Larimar Therapeutics, Inc. LRMR
2.53 USD +0.14 (+5.86%)
At closeNov 9, 2026, 5:44 PM EST
2.58 +0.05 +1.98%
After hours · Nov 9, 5:44 PM ET
2.37 Day range 2.58
1.92 52-week range 6.42
- YTD
- -33.60%
- 1 year
- -26.88%
News
benzinga.com Larimar Therapeutics Completes Rolling BLA Submission To FDA Seeking Accelerated Approval Of Nomlabofusp For Treatment Of Patients With Friedreich’s Ataxia Completed BLA submission marks a major milestone in advancing nomlabofusp as the first potential disease-modifying therapy to address the underlying cause of FA Submission follows FDA alignment on…
globenewswire.com Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference BALA CYNWYD, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare…
benzinga.com Larimar Therapeutics Appoints John Harlow As President and COO, Effective September 29 Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of John Harlow…
benzinga.com Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $11 Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $12 to $11.
benzinga.com Larimar Therapeutics Q2 EPS $(0.30) Beats $(0.39) Estimate Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.39) by 23.08 percent. This is a 26.83 percent increase over losses…- benzinga.com HC Wainwright & Co. Assumes Larimar Therapeutics at Buy, Announces Price Target of $10 HC Wainwright & Co. analyst Raghuram Selvaraju assumes Larimar Therapeutics (NASDAQ:LRMR) with a Buy rating and announces Price Target of $10.
benzinga.com Baird Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $5 Baird analyst Joel Beatty maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $7 to $5.
benzinga.com Larimar Stock Slides 15% Despite FDA Backing Rolling Submission For Rare Disease Drug Larimar Therapeutics Inc (LRMR) submits first module of Biologics License Application for investigational treatment for Friedreich's ataxia, with FDA support and positive long-term data showing…
benzinga.com Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrollment of first patient in phase 3 trial.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 159.6% to $7.68 during Monday's pre-market session. The company's market cap stands at $1.9 million. Decoy Therapeutics…
benzinga.com Why Universe Pharmaceuticals Shares Are Trading Higher By Around 228%; Here Are 20 Stocks Moving Premarket Universe Pharmaceuticals Inc (NASDAQ: UPC) surged 228.4% to $9.72 in pre-market trading after announcing acquisition of Best Praise International for $10.75 million.- benzinga.com Larimar Therapeutics Submits First Module Of Rolling BLA Submission To FDA For Accelerated Approval Of Nomlabofusp; Remaining Modules Expected To Be Submitted In H2 2026 FDA alignment on submission of BLA data package in multi-disciplinary Type B pre-BLA meeting minutes; first module of rolling BLA submitted with remaining modules expected 2H 2026 Daily nomlabofusp…
benzinga.com JP Morgan Initiates Coverage On Larimar Therapeutics with Overweight Rating, Announces Price Target of $9 JP Morgan analyst Tessa Romero initiates coverage on Larimar Therapeutics (NASDAQ:LRMR) with a Overweight rating and announces Price Target of $9.
benzinga.com Nvidia To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Monday Top analysts changed outlook on top names. Keybanc, Leerink, Wedbush, DA Davidson, Benchmark, Piper Sandler, Morgan Stanley, Evercore raised price targets.- benzinga.com Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $12 Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $13 to $12.
- benzinga.com Larimar Therapeutics Q1 EPS $(0.31) Beats $(0.54) Estimate Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.54) by 42.59 percent. This is a 32.61 percent increase over losses…
- benzinga.com Wedbush Maintains Outperform on Larimar Therapeutics, Raises Price Target to $13 Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and raises the price target from $12 to $13.
benzinga.com Earnings Scheduled For March 19, 2026 - benzinga.com Larimar Therapeutics Q4 EPS $(0.73) Misses $(0.45) Estimate Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.45) by 62.22 percent. This is a 62.22 percent decrease over losses…
benzinga.com Wedbush Maintains Outperform on Larimar Therapeutics, Raises Price Target to $12 Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and raises the price target from $11 to $12.
benzinga.com C3.ai Posts Downbeat Results, Joins Trade Desk, FTAI Aviation And Other Big Stocks Moving Lower In Thursday's Pre-Market Session 
benzinga.com Why Marriott Vacations Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket - benzinga.com Larimar Therapeutics Commences $75M Common Stock Offering Larimar Therapeutics, Inc. ("Larimar") (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an…
benzinga.com Laminar Therapeutics Stock Is Popping Today: What's Going On? Larimar Therapeutics Inc (NASDAQ:LRMR) shares are soaring on Wednesday after multiple analysts reiterated their bullish outlook.- benzinga.com Citigroup Maintains Buy on Larimar Therapeutics, Raises Price Target to $14 Citigroup analyst Samantha Semenkow maintains Larimar Therapeutics (NASDAQ:LRMR) with a Buy and raises the price target from $12 to $14.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com Acadia Healthcare Posts Upbeat Q4 Earnings, Joins Circle Internet, Resideo Technologies And Other Big Stocks Moving Higher On Wednesday - benzinga.com Wedbush Reiterates Outperform on Larimar Therapeutics, Maintains $11 Price Target Wedbush analyst Laura Chico reiterates Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and maintains $11 price target.
benzinga.com Nasdaq Gains Over 1%; Keurig Dr Pepper Earnings Top Views 
benzinga.com Larimar Therapeutics (LRMR) Surges On FDA Breakthrough Therapy Designation Larimar Therapeutics Inc (NASDAQ: LRMR) shares are trading sharply higher Tuesday after the company said the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to its…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com Dow Gains Over 100 Points; Home Depot Posts Upbeat Earnings 
benzinga.com Top 3 Health Care Stocks That May Rocket Higher In December - benzinga.com Larimar Therapeutics Q3 EPS $(0.61) Misses $(0.40) Estimate Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.40) by 51.36 percent. This is a 154.17 percent decrease over…
benzinga.com Quantum Computing, Mesoblast And Other Big Stocks Moving Lower In Monday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands at $5.5 million. Zura Bio (NASDAQ: ZURA) stock moved upwards by 42.94% to $3.44.…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The market value of their outstanding shares is at $10.5 million.- benzinga.com Market-Moving News for September 29th LRMR: -53% | Larimar shares are trading lower after the company reported seven patients experienced anaphylaxis and were withdrawn from its long-term study evaluating daily subcutaneous injections of
benzinga.com Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com Crude Oil Down 1%; Webuy Global Shares Spike Higher
- benzinga.com G-III Apparel Posts Upbeat Results, Joins NIO, Yext, Shoe Carnival And Other Big Stocks Moving Higher On Thursday
- benzinga.com Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
benzinga.com Ambarella Posts Upbeat Results, Joins Gap, PagerDuty, Elastic And Other Big Stocks Moving Higher On Friday - benzinga.com Why James Hardie Industries Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- benzinga.com Why Larimar Therapeutics Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com Over $37M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying Although U.S. stocks closed lower on Friday, there were a few notable insider trades.